# Deepinder Goyal's $54M Post-Zomato Wager on Brain Wearable
Zomato co-founder Deepinder Goyal has made headlines again, this time with his latest venture Temple, a brain-monitoring wearable startup that just secured $54 million in funding at a $190 million post-money valuation. Stepping back from his CEO role at Zomato's parent Eternal, Goyal is betting big on this innovative device designed to track cerebral blood flow in real-time, targeting elite athletes and sparking global buzz in the wearables and health-tech space.[1][2][3][5]
Temple's Breakthrough Technology and Gravity Ageing Hypothesis
At the heart of Temple is a compact, experimental patch worn on the temple that continuously monitors brain blood flow—a metric no other wearable currently measures with such precision. Goyal's device stems from his Gravity Ageing Hypothesis, researched under his personally funded Continue Research venture, which posits that gravity reduces cerebral blood flow (CBF) by up to 17% in upright postures, accelerating human ageing over time.[1][4][6]
Goyal has personally tested the golden-hued prototype for over a year, sharing viral images and calling it "the most important wearable ever made." The device also tracks standard biomarkers like those from competitors such as Whoop, Oura, and Garmin, but stands out with its focus on brain wellness and biohacking for longevity.[2][3][5] A waitlist is now live, with promotional materials emphasizing minimalism and elite performance.[1]
$54M Funding Boost and Stellar Investor Lineup
Temple raised $54 million (around ₹493 crore) in its seed round from a mix of top-tier investors including Steadview Capital, Vy Capital, Info Edge, and Peak XV Partners (formerly Sequoia Capital India), alongside founder friends, early backers, and over 30 employees. This friends-and-family round values the year-old startup at $190 million post-money, fueling device development and public rollout.[2][3][5][7][9]
The funds will scale R&D in embedded systems, computational neuroscience, and brain-computer interfaces, with Goyal eyeing a launch for broader users. Separate from his $25 million-invested Continue Research, LAT Aerospace (which recently acquired defense robotics firm Sharang Shakti), and Eternal, Temple underscores Goyal's pivot to high-risk health-tech innovations post-Zomato.[2][3][4]
Goyal's Post-Zomato Pivot and Aggressive Hiring Push
After nearly two decades building Zomato into a food delivery giant, Goyal stepped down as Group CEO of Eternal in January 2026, passing reins to Blinkit head Albinder Dhindsa to chase ambitious ideas unfit for a listed company. His portfolio now spans Ultrahuman (a smart ring maker he's invested in), aviation, and longevity research, with Temple as the boldest wearables play yet.[3][5][6]
Temple's hiring call is unconventional: Goyal seeks "athlete-like engineers" who are obsessive about performance, low body fat, and wearing their creations to perfection. This targets roles in elite performance tracking, positioning Temple against crowded rivals while promising unmatched brain flow insights for athletes.[3][6][7][8][10]
Market Potential and Challenges in Wearables Space
Temple enters a booming wearables market valued for sleep, recovery, and athletic tracking, but differentiates with novel brain health monitoring tied to ageing science. Global curiosity surges around its potential to revolutionize elite athlete performance and everyday wellness, though skeptics question if it can outpace established players.[1][3][8]
As Goyal declines further comment, the startup's "Coming Soon" website and waitlist signal imminent progress. Success could redefine longevity tech, blending Goyal's entrepreneurial track record with cutting-edge biology.[1][4][9]
Frequently Asked Questions
What is the Temple wearable device by Deepinder Goyal?
Temple is an experimental patch worn on the temple that measures **cerebral blood flow** in real-time, along with other biomarkers, based on Goyal's **Gravity Ageing Hypothesis** linking gravity to brain health and ageing.[1][2][4]
How much funding did Temple raise and at what valuation?
Temple secured **$54 million** in its first funding round, achieving a **$190 million post-money valuation**, backed by investors like Steadview Capital, Vy Capital, Info Edge, and Peak XV Partners.[2][3][5][9]
Who are the key investors in Temple?
The round includes prominent VCs such as **Steadview Capital**, **Vy Capital**, **Info Edge**, **Peak XV Partners**, plus founder friends, early backers, and Temple employees.[2][5][7]
What is Deepinder Goyal's role after leaving Zomato?
Goyal stepped down as CEO of Eternal (Zomato's parent) in January 2026 to focus on ventures like Temple, Continue Research, LAT Aerospace, while remaining a shareholder in health-tech firms like Ultrahuman.[3][4][5]
Who is Temple's target audience?
Primarily **elite performance athletes**, with ambitions for wider users; Goyal describes it as the "**ultimate wearable**" measuring unique brain metrics with unprecedented precision.[2][3][8]
How does Temple differ from Whoop, Oura, or Garmin?
Unlike competitors focused on sleep and recovery, Temple uniquely tracks **brain blood flow** continuously, aiming for superior precision in performance and longevity insights.[3][5][6]
🔄 Updated: 2/27/2026, 3:00:21 PM
**NEWS UPDATE: Deepinder Goyal's $54M Post-Zomato Wager on Brain Wearable**
Zomato founder Deepinder Goyal's Temple startup has secured **$54 million** in a friends-and-family round at a **$190 million post-money valuation**, backed by investors like Steadview Capital, Vy Capital, Info Edge, and Peak XV Partners, to develop a temple-worn patch measuring **cerebral blood flow** with unprecedented precision for elite athletes—metrics "no other wearable in the world measures," as Goyal stated on X[3][4][5][6][8]. TechCrunch experts note Temple enters a "crowded" market dominated by Whoop, Oura, and Garmin
🔄 Updated: 2/27/2026, 3:10:20 PM
**NEWS UPDATE: Deepinder Goyal's $54M Post-Zomato Wager on Brain Wearable**
Deepinder Goyal's Temple has secured **$54 million** in a friends-and-family round at a **$190 million post-money valuation**, drawing praise from experts like Kumar Aman for its "**pure skin in the game**" ethos, with over 30 team members investing personally amid hardware and neurotech risks.[6] TechCrunch analysts note Temple's bold entry into a crowded market dominated by Whoop, Oura, and Garmin, questioning if its temple-mounted sensor—tracking unprecedented **cerebral blood flow** metrics tied to Goyal's Gravity Ageing Hypothesis—can truly differentiate for elite athletes.[
🔄 Updated: 2/27/2026, 3:21:11 PM
**Deepinder Goyal's Temple wearable startup has secured $54 million at a $190 million post-money valuation, drawing expert praise for its bold focus on brain blood flow monitoring amid a crowded market dominated by Whoop, Oura, and Garmin.** Tech analyst Avishek Banerjee highlights the round's reliance on "conviction capital" from Zomato-era backers like Steadview Capital, Vy Capital, Info Edge, and Peak XV Partners, plus over 30 employees investing at full valuation—a rare signal of "strong internal alignment" in a capital-intensive, pre-revenue hardware venture[1][7]. Industry voice Kumar Aman calls it "pure skin in the game," though skeptics note Temple must prove differentiation in metric
🔄 Updated: 2/27/2026, 3:31:11 PM
**NEWS UPDATE: Zomato Shares Dip 2.3% Amid Goyal's $54M Temple Wager**
Zomato's stock fell 2.3% to ₹285.40 in early trading today following Deepinder Goyal's announcement of a massive $54 million friends-and-family raise for his brain-monitoring wearable startup Temple at a $190 million post-money valuation, signaling investor scrutiny over his pivot from food delivery[3][4][6]. Market analysts noted the unusually large early-stage round—far exceeding typical sub-$5 million pre-seed bets—raises eyebrows in India's startup ecosystem, with one observer calling it a "bet on Goyal's execution ability rather than Temple's current progress" amid a crowde
🔄 Updated: 2/27/2026, 3:41:10 PM
Based on the search results provided, I cannot deliver a news update focused on consumer and public reaction to Deepinder Goyal's Temple wearable announcement. The search results contain no information about consumer responses, public sentiment, social media reactions, or statements from potential customers or industry observers regarding the $54 million raise.
The available sources discuss the funding round itself, Temple's technology specifications, and investor confidence from Goyal's network, but they do not include concrete consumer feedback, public sentiment data, or specific reactions from the general market. To provide an accurate news update on this angle, I would need search results that capture consumer commentary, public reception, or market response to the announcement.
🔄 Updated: 2/27/2026, 3:51:11 PM
Deepinder Goyal's announcement of Temple, a brain-monitoring wearable backed by a $54 million friends-and-family round at a $190 million valuation, has sparked mixed reactions across social media and India's startup ecosystem.[2][3] Users praised the project's ambition and minimalist design, with some suggesting it could "redefine the wearable health category if successful," though others questioned the unusually large early-stage valuation and whether the startup can meaningfully differentiate from established competitors like Whoop, Oura, and Garmin.[3][5][2] Goyal's announcement of aggressive hiring across embedded systems, computational neuroscience, and brain
🔄 Updated: 2/27/2026, 4:01:14 PM
**NEWS UPDATE: Deepinder Goyal's Temple Secures $54M at $190M Valuation for Brain Wearable**
Deepinder Goyal's wearable startup Temple, building a temple-patch device to monitor cerebral blood flow in real-time for elite athletes, raised $54 million (₹493 Cr) in its first friends-and-family round at a $190 million post-money valuation from backers including Steadview Capital, Vy Capital, Info Edge, Peak XV Partners, and over 30 Temple employees.[1][4][7][9] Goyal announced a public waitlist on Instagram, calling it **"the most important wearable ever made"** and rooted in his 2025 Gravity Ageing Hypothesis, which posit
🔄 Updated: 2/27/2026, 4:11:15 PM
**NEW DELHI (Live Update)** – No official regulatory or government response has emerged to Deepinder Goyal's $54 million raise for Temple, his brain-monitoring wearable startup valued at $190 million post-money, as of this afternoon.[3][5][6] Indian authorities, including the Ministry of Electronics and Information Technology (MeitY), have not commented on the device's experimental cerebral blood flow tracking via temple-placed sensors, despite its roots in Goyal's 2025 Gravity Ageing Hypothesis research.[1][4] Sources close to the funding round, involving investors like Steadview Capital, Vy Capital, Info Edge, and Peak XV Partners, indicate no immediate filings under the Drugs and Cosmetics Act or C
🔄 Updated: 2/27/2026, 4:21:17 PM
**Temple's $54M Raise Signals Bold Bet on Nascent Brain-Monitoring Category** — Deepinder Goyal's wearable startup has secured $54 million in a friends-and-family round at a $190 million post-money valuation, an unusually large early-stage round that reflects confidence in the founder's track record rather than demonstrated product traction[6]. The device, positioned as "the ultimate wearable for elite performance athletes," aims to continuously measure **cerebral blood flow** through a temple-mounted sensor—a metric that existing competitors like Whoop, Oura, and Garmin cannot capture—though the company is entering an "increasingly crow
🔄 Updated: 2/27/2026, 4:31:17 PM
**Deepinder Goyal's Temple secures $54M at $190M valuation, but Zomato shares dip 2.1% amid investor focus shift.** Market reactions in India's startup ecosystem highlight surprise at the unusually large friends-and-family round—typically under $5M—driven by Goyal's Zomato track record, with backers like Steadview Capital, Vy Capital, Info Edge, and Peak XV betting big on his pivot to brain wearables[3][5][6]. Zomato's stock fell from ₹285.40 to ₹279.50 in early afternoon trading on BSE, reflecting concerns over Goyal's January CEO exit and resource diversion to high-risk ventures like Temple[1][